Rofecoxib for dysmenorrhoea: meta-analysis using individual patient data

[1]  B. Türkkani,et al.  Dysmenorrhea treatment with a single daily dose of rofecoxib , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[2]  C. Farquhar,et al.  Nonsteroidal anti-inflammatory drugs for primary dysmenorrhoea. , 2003, The Cochrane database of systematic reviews.

[3]  P. Desjardins,et al.  Analgesic Efficacy of Etoricoxib in Primary Dysmenorrhea: Results of a Randomized, Controlled Trial , 2003, Gynecologic and Obstetric Investigation.

[4]  I. Milsom,et al.  Comparison of the efficacy and safety of nonprescription doses of naproxen and naproxen sodium with ibuprofen, acetaminophen, and placebo in the treatment of primary dysmenorrhea: a pooled analysis of five studies. , 2002, Clinical therapeutics.

[5]  S. Talwalker,et al.  Valdecoxib, a Cyclooxygenase‐2‐Specific Inhibitor, Is Effective in Treating Primary Dysmenorrhea , 2002, Obstetrics and gynecology.

[6]  R. Moore,et al.  Teasing apart quality and validity in systematic reviews: an example from acupuncture trials in chronic neck and back pain , 2000, Pain.

[7]  J. L. Tang,et al.  Misleading funnel plot for detection of bias in meta-analysis. , 2000, Journal of clinical epidemiology.

[8]  D. Gavaghan,et al.  An evaluation of homogeneity tests in meta-analyses in pain using simulations of individual patient data , 2000, Pain.

[9]  I. Olkin,et al.  Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement , 1999, The Lancet.

[10]  S. Daniels,et al.  Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. , 1999, Obstetrics and gynecology.

[11]  J. Keogh,et al.  Primary dysmenorrhea in young Western Australian women: prevalence, impact, and knowledge of treatment. , 1999, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[12]  D. Gavaghan,et al.  Size is everything – large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects , 1998, Pain.

[13]  Weiya Zhang,et al.  Efficacy of minor analgesics in primary dysmenorrhoea: a systematic review , 1998, British journal of obstetrics and gynaecology.

[14]  M. Tramèr,et al.  Impact of covert duplicate publication on meta-analysis: a case study , 1997, BMJ.

[15]  A. Hewison,et al.  Dysmenorrhoea, menstrual attitude and GP consultation. , 1996, British journal of nursing.

[16]  A. Jadad,et al.  The importance of quality of primary studies in producing unbiased systematic reviews. , 1996, Archives of internal medicine.

[17]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[18]  C. Kainz,et al.  Concentrations of various arachidonic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives. , 1995, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[19]  D. Sackett,et al.  The number needed to treat: a clinically useful measure of treatment effect , 1995 .

[20]  M. Dawood.  Nonsteroidal antiinflammatory drugs and reproduction. , 1993, American journal of obstetrics and gynecology.

[21]  D. Hill.  Statistics with Confidence: Confidence Intervals and Statistical Guidelines , 1990 .

[22]  Dawood My.  Nonsteroidal anti-inflammatory drugs and changing attitudes toward dysmenorrhea. , 1988 .

[23]  K A L'Abbé,et al.  Meta-analysis in clinical research. , 1987, Annals of internal medicine.

[24]  E. Franco,et al.  BMC Women's Health , 2004 .

[25]  S. Nigam,et al.  Increased concentrations of eicosanoids and platelet-activating factor in menstrual blood from women with primary dysmenorrhea. , 1991, Eicosanoids.

[26]  Douglas G. Altman,et al.  Statistics with confidence: Confidence intervals and statistical guidelines . , 1990 .